3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
31
Carcinoma, Intraductal, Noninfiltrating
3
Ovarian Neoplasms
2
Neoplasms
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Locoregional Recurrence
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Granulosa cell tumor of the ovary
1
Endometrial Neoplasms
1
Carcinoma, Ductal
1
Breast Carcinoma In Situ
1
Anatomic Stage III Breast Cancer AJCC v8
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Carcinoma
1
Advanced Breast Cancer
1
Acrocephalosyndactylia
1
Interventions
exemestane
2
Tamoxifen
2
Letrozole
2
Immunotherapy
2
Anastrozole
2
ribociclib
1
elacestrant
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
abemaciclib
1
Taxes
1
Standard of Care
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Practice Guidelines as Topic
1
Neoadjuvant Therapy
1
Methods
1
Mental Status and Dementia Tests
1
Leuprolide
1
Interviews as Topic
1
Goserelin
1
Genetic Testing
1
Genetic Counseling
1
Educational Status
1
Early Intervention, Educational
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms, Male
×
exemestane
×
90 days
×
Clear all
NCT05827081
2026-06-03
Adjuvant WIDER
Novartis
Phase 3
Recruiting
1,400 enrolled
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled